ScreenerHero

MIRM Mirum Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · mirumpharma.com
79.73USD-1.13%Mkt Cap: 5.24B $P/E: —

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.24B USD
Enterprise Value5.47B USD
Revenue (TTM)618.07M USD
Gross Profit421.07M USD
Net Income (TTM)-23.36M USD
Revenue/Share11.02 USD
Last Price79.73 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees433
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-228.60
PEG—
EV/EBITDA-77.84
EV/Revenue8.85
P/S8.33
P/B-492.24
EPS (TTM)-13.72
EPS (Forward)-0.35
52W Range
63.2325% of range130.00
52W High130.00 USD
52W Low63.23 USD
Profitability
Gross Margin80.77%
Oper. Margin-14.81%
EBITDA Margin-11.37%
Profit Margin-4.48%
ROE-7.42%
ROA-2.77%
Growth
Revenue Growth37.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF55.83M USD
CapEx (TTM)954.00K USD
FCF Margin12.40%
FCF Yield1.46%
Net Debt324.66M USD
Net Debt/EBITDA-4.62
Balance Sheet
Debt/Equity1.02
Current Ratio2.86
Quick Ratio2.62
Book Value/Sh-0.16 USD
Cash/Share6.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)145.79 USD
Upside (mean)+82.8%
Target Range118.00 USD – 195.00 USD
118.00+82.8% to mean195.00
# Analysts14
Ownership
Shares Out.64.93M
Float56.42M
Insiders1.29%
Institutions111.77%
Short Interest
Short Ratio12.5d
Short % Float12.45%
Short % Out.9.67%
Shares Short6.28M
Short (prev mo.)6.49M
Technical
SMA 5097.57 (-18.3%)
SMA 20098.33 (-18.9%)
Beta0.61
S&P 52W Chg16.45%
Avg Vol (30d)711.90K
Avg Vol (10d)852.00K
Technical Indicators
RSI (14)24.6
MACD-5.1914
MACD Signal-4.4671
MACD Hist.-0.7243
BB Upper103.02 USD
BB Middle90.00 USD
BB Lower76.98 USD
BB Width28.93%
ATR (14)3.864 USD
Vol Ratio (20d)1.28x